<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513369</url>
  </required_header>
  <id_info>
    <org_study_id>CLEVER-2011</org_study_id>
    <secondary_id>2011-005224-18</secondary_id>
    <nct_id>NCT01513369</nct_id>
  </id_info>
  <brief_title>Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency</brief_title>
  <acronym>CLEVER</acronym>
  <official_title>Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the correlation between HbA1c and iron status in&#xD;
      Type 2 Diabetes mellitus patients with iron deficiency by intravenous substitution of iron.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in HBA1c-levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>reduction of HbA1c from week 1 (baseline) to week 13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of haematological and iron status</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hb, MCV, MCH, hypochromic cells, reticulocyte Hb content, ferritin, transferrin, transferrin saturation (TSAT), sTFR, iron, hepcidin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>potential clinical improvement and improvement in quality of life (EQ5D) of patients with ID T2DM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of metabolic status</measure>
    <time_frame>12 weeks</time_frame>
    <description>measurement of fasting glucose, fructosamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reliability of HbA1c-measurements</measure>
    <time_frame>12 weeks</time_frame>
    <description>measurement of HbA1c in week 0; 5 and 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in vascular function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in vascular function on the basis of the biomarker ADMA serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in used insulin dosage during study</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in used insulin dosage during study (via patient diary)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl (0,9%)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric carboxymaltose</intervention_name>
    <description>Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous</description>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <other_name>Ferinject (marketing authorization number: 66227.00.00)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl (0,9%)</intervention_name>
    <description>Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous</description>
    <arm_group_label>NaCl (0,9%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        T2DM patients with diagnosis of ID defined as follows:&#xD;
&#xD;
          -  serum ferritin &lt;150 ng/mL or TSAT &lt;25% if Hb &lt; 14 g/dL serum ferritin &lt;100 ng/mL or&#xD;
             TSAT &lt;20% if Hb ≥ 14 g/dL and ≤ 15g/dL]&#xD;
&#xD;
          -  HbA1c: ≥ 6.5 to &lt; 8.5 %&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent has been obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Continuous subcutaneous insulin infusion (CSII)&#xD;
&#xD;
          -  thalassaemia&#xD;
&#xD;
          -  Hb &gt; 15 g/dL (&gt; 9,31 mmol/L)&#xD;
&#xD;
          -  Change of HbA1c of more than ±0,3 % within the last 3 months.&#xD;
&#xD;
          -  known sensitivity to ferric carboxymaltose&#xD;
&#xD;
          -  history of acquired iron overload&#xD;
&#xD;
          -  History of erythropoietin stimulating agent, i.v. iron therapy, and/or blood&#xD;
             transfusion in previous 12 weeks prior to randomisation&#xD;
&#xD;
          -  History of oral iron therapy at doses ≥ 100 mg/day 1 week prior to randomisation.&#xD;
             Note: Ongoing oral use of multivitamins containing iron &lt; 75 mg/day is permitted.&#xD;
&#xD;
          -  Body weight ≤ 40 kg&#xD;
&#xD;
          -  CRP &gt; 15 mg/L&#xD;
&#xD;
          -  Chronic liver disease (including known active hepatitis) and/or screening alanine&#xD;
             transaminase (ALAT) or aspartate transaminase (ASAT) &gt; 3 x ULN (upper limit of the&#xD;
             normal range).&#xD;
&#xD;
          -  Subjects with known hepatitis B surface antigen positivity and/or Hepatitis C virus&#xD;
             ribonucleic acid positivity.&#xD;
&#xD;
          -  Vitamin B12 and/or serum folate deficiency. If deficiency corrected subject may be&#xD;
             rescreened for inclusion.&#xD;
&#xD;
          -  Subjects with known seropositivity to human immunodeficiency virus.&#xD;
&#xD;
          -  Clinical evidence of current malignancy with exception of basal cell or squamous cell&#xD;
             carcinoma of the skin, and cervical intraepithelial neoplasia.&#xD;
&#xD;
          -  Currently receiving systemic chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Renal dialysis (previous, current or planned within the next 6 months).&#xD;
&#xD;
          -  Renal function GFR &lt; 30 mL/min/ 1.73m2 (severe)&#xD;
&#xD;
          -  Unstable angina pectoris as judged by the Investigator; severe valvular or left&#xD;
             ventricular outflow obstruction disease needing intervention; atrial&#xD;
             fibrillation/flutter with a mean ventricular response rate at rest &gt;100 beats per&#xD;
             minute.&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or&#xD;
             stroke within the last 3 months prior to randomisation.&#xD;
&#xD;
          -  Coronary-artery bypass graft, percutaneous intervention (e.g., cardiac,&#xD;
             cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including&#xD;
             thoracic and cardiac surgery, within the last 3 months prior to randomisation.&#xD;
&#xD;
          -  Patients with a polyneuropathy without ischemia.&#xD;
&#xD;
          -  Subject of child-bearing potential who is pregnant (e.g., positive human chorionic&#xD;
             gonadotropin test) or is breast feeding.&#xD;
&#xD;
          -  Any subject not willing to use adequate contraceptive precautions during the study and&#xD;
             for up to 5 days after the last scheduled dose of study medication.&#xD;
&#xD;
          -  Participation in other interventional trials&#xD;
&#xD;
          -  Female subject of child-bearing potential who is pregnant (e.g., positive human&#xD;
             chorionic gonadotropin test) or is breast feeding.&#xD;
&#xD;
          -  Failure to use highly-effective contraceptive methods&#xD;
&#xD;
          -  Persons with any kind of dependency on the investigator or employed by the sponsor or&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Schindler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>on behalf of GWT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Grüneberg, Mehring, Stude</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univesitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Professor Hanefeld Abakus Büropark</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinisches Forschungszentrum CRC</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetesinstitut Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>iron deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

